Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Macitentan/Tadalafil FDC vs Free Combination
NCT03215966Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of macitentan and tadalafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve from 0 to time t and 1 more. Started Aug 2017; status: completed.
02
Drugs
macitentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03215966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215966.